Federal Circuit Considers Revising Injunction on Avadel’s Sleep Disorder Drug Marketing

In a recent development, judges on the Federal Circuit have shown a willingness to revisit a district court’s injunction that currently prevents Avadel Pharmaceuticals from marketing its narcolepsy drug for the treatment of another sleep disorder. The case involves the specialty drugmaker’s effort to expand the use of its existing product beyond narcolepsy, which is at the heart of the legal proceedings. The potential modification of the injunction could have significant implications for Avadel Pharmaceuticals’ business strategy concerning the drug in question. For further details, you can read more in the coverage by Law360.